|
US6297239B1
(en)
|
1997-10-08 |
2001-10-02 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
US6566372B1
(en)
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
|
US6462076B2
(en)
|
2000-06-14 |
2002-10-08 |
Hoffmann-La Roche Inc. |
Beta-amino acid nitrile derivatives as cathepsin K inhibitors
|
|
CA2422057C
(en)
|
2000-09-08 |
2012-11-27 |
Prozymex A/S |
Dipeptidyl peptidase i crystal structure and its uses
|
|
US20110236367A1
(en)
|
2000-09-08 |
2011-09-29 |
Telenav, Inc. |
Rat cathespin dipeptidyl peptidase i (dppi): crystal structure and its uses
|
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
|
HUP0402344A2
(hu)
|
2001-12-04 |
2005-02-28 |
F. Hoffmann-La Roche Ag |
Helyettesített 2-amino-cikloalkán-karboxamidok, felhasználásuk cisztein-proteáz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
|
|
US20040253311A1
(en)
|
2002-12-18 |
2004-12-16 |
Roger Berlin |
Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
|
|
WO2004076434A1
(en)
|
2003-02-28 |
2004-09-10 |
Aic |
Dipeptidyl peptidase inhibitors
|
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
|
EP1633702B1
(en)
|
2003-05-30 |
2008-07-02 |
Prozymex A/S |
Protease inhibitors
|
|
JP2006527704A
(ja)
|
2003-06-18 |
2006-12-07 |
プロザイメックス・アクティーゼルスカブ |
プロテアーゼ阻害剤
|
|
EP3372614B1
(en)
|
2004-04-07 |
2022-06-08 |
Rinat Neuroscience Corp. |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
|
EP1745292A2
(en)
|
2004-04-28 |
2007-01-24 |
Bayer HealthCare AG |
Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
|
|
US7618981B2
(en)
|
2004-05-06 |
2009-11-17 |
Cytokinetics, Inc. |
Imidazopyridinyl-benzamide anti-cancer agents
|
|
PL1916994T3
(pl)
|
2004-06-29 |
2014-05-30 |
Takeda Pharma As |
Wytwarzanie kompozycji farmaceutycznej o szybkim uwalnianiu leków nierozpuszczalnych w wodzie i kompozycje farmaceutyczne otrzymywane sposobem według wynalazku
|
|
CN103251953A
(zh)
|
2004-07-19 |
2013-08-21 |
约翰·霍普金斯大学 |
供免疫抑制的flt3抑制剂
|
|
KR20070114753A
(ko)
|
2005-02-18 |
2007-12-04 |
아브락시스 바이오사이언스 인크. |
치료제의 조합 및 투여 방식, 및 조합 요법
|
|
WO2007005668A2
(en)
|
2005-06-30 |
2007-01-11 |
Amgen Inc. |
Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
|
|
JP2010520293A
(ja)
|
2007-03-07 |
2010-06-10 |
アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド |
複素環式部分を含有するメタロプロテアーゼ阻害剤
|
|
TW200916447A
(en)
|
2007-08-29 |
2009-04-16 |
Methylgene Inc |
Sirtuin inhibitors
|
|
MX2010003263A
(es)
|
2007-09-25 |
2010-06-02 |
Novartis Ag |
Tratamiento de trastornos pulmonares con medicamentos aerosolizados tales como vancomicina.
|
|
US7902181B2
(en)
|
2007-12-12 |
2011-03-08 |
Astrazeneca Ab |
Compounds 010
|
|
US9315449B2
(en)
|
2008-05-15 |
2016-04-19 |
Duke University |
Substituted pyrazoles as heat shock transcription factor activators
|
|
PE20100252A1
(es)
|
2008-06-06 |
2010-04-12 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
|
|
JP5752601B2
(ja)
|
2008-12-08 |
2015-07-22 |
ブイエム ファーマ エルエルシー |
タンパク質受容体チロシンキナーゼ阻害薬の組成物
|
|
BRPI1016132B8
(pt)
|
2009-04-01 |
2021-05-25 |
Bial Portela & Ca Sa |
composição, formulação farmacêutica, processo de obtenção de uma formulação farmacêutica estável
|
|
MX2011011661A
(es)
|
2009-05-07 |
2011-11-18 |
Astrazeneca Ab |
Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
|
|
WO2010142985A1
(en)
|
2009-06-10 |
2010-12-16 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
|
|
HRP20211752T1
(hr)
*
|
2010-04-07 |
2022-02-18 |
Vertex Pharmaceuticals Incorporated |
Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
|
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
|
WO2012119941A1
(en)
|
2011-03-04 |
2012-09-13 |
Prozymex A/S |
Peptidyl nitrilcompounds as peptidase inhibitors
|
|
US8999975B2
(en)
|
2011-09-19 |
2015-04-07 |
Boehringer Ingelheim International Gmbh |
Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
|
|
CN104114557B
(zh)
|
2012-02-21 |
2017-10-24 |
默克专利股份公司 |
作为syk酪氨酸激酶抑制剂和gcn2丝氨酸激酶抑制剂的8‑取代2‑氨基‑[1,2,4]三唑并[1,5‑a]吡嗪
|
|
EP2840083B1
(en)
|
2012-04-17 |
2017-09-13 |
Astellas Pharma Inc. |
Nitrogenated bicyclic aromatic heterocyclic compound
|
|
WO2014091443A1
(en)
|
2012-12-13 |
2014-06-19 |
Glaxo Group Limited |
Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
|
|
EP2775304A1
(en)
|
2013-03-07 |
2014-09-10 |
Universitätsspital Basel |
Methods for detecting inflammatory disorder
|
|
EP2970252B1
(en)
|
2013-03-14 |
2020-06-03 |
Boehringer Ingelheim International GmbH |
Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
|
|
JP6437929B2
(ja)
|
2013-03-14 |
2018-12-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
|
|
ES2845473T3
(es)
|
2013-03-14 |
2021-07-26 |
Boehringer Ingelheim Int |
(Bencil-ciano-metil)-amidas sustituidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico inhibidores de la catepsina- C
|
|
EP2970228B1
(en)
|
2013-03-14 |
2017-05-10 |
Boehringer Ingelheim International GmbH |
Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin c
|
|
UY35400A
(es)
|
2013-03-15 |
2014-10-31 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de enfermedades parasitarias
|
|
AU2014248455B2
(en)
|
2013-04-01 |
2018-12-06 |
Pulmatrix Operating Company, Inc. |
Tiotropium dry powders
|
|
WO2015027039A1
(en)
|
2013-08-22 |
2015-02-26 |
Emory University |
Devices and methods related to airway inflammation
|
|
EP3044214B1
(en)
|
2013-09-09 |
2017-08-09 |
ProZymex A/S |
Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
|
|
WO2015032942A1
(en)
|
2013-09-09 |
2015-03-12 |
Prozymex A/S |
N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
|
|
GB201400034D0
(en)
*
|
2014-01-02 |
2014-02-19 |
Astrazeneca Ab |
Pharmaceutical Compositions comprising AZD9291
|
|
NO2699580T3
(enExample)
|
2014-01-24 |
2018-02-24 |
|
|
|
GB201402070D0
(en)
*
|
2014-02-07 |
2014-03-26 |
Galapagos Nv |
Pharmaceutical compositions for the treatment of inflammatory disorders
|
|
EP3129020A1
(en)
*
|
2014-04-10 |
2017-02-15 |
Novartis AG |
S1p modulator immediate release dosage regimen
|
|
LT3466432T
(lt)
|
2014-05-15 |
2020-12-28 |
Insmed Incorporated |
Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
|
|
WO2015180687A1
(en)
|
2014-05-30 |
2015-12-03 |
The University Of Hong Kong |
Methods and compositions for use of neutrophil elastase and proteinase 3 as diagnostic biomarkers
|
|
JP6529575B2
(ja)
|
2014-08-01 |
2019-06-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用
|
|
EP3511331A1
(en)
|
2014-09-12 |
2019-07-17 |
Boehringer Ingelheim International GmbH |
Spirocyclic inhibitors of cathepsin c
|
|
BR112017009595A2
(pt)
|
2014-11-14 |
2017-12-19 |
Boehringer Ingelheim Int |
morfolina e 1,4-oxazepano amidas como agonistas do subtipo de receptor de somatostatina 4 (sstr4)
|
|
JP6783426B2
(ja)
|
2015-03-05 |
2020-11-11 |
ニュープロザイム・セラピューティクス・アンパルトセルスカブＮｅｕｐｒｏｚｙｍｅ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡｐＳ |
ジペプチジルペプチダーゼｉ阻害剤としてのペプチジルニトリル化合物
|
|
KR20240091302A
(ko)
*
|
2016-07-29 |
2024-06-21 |
인스메드 인코포레이티드 |
기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드
|
|
CA3089240A1
(en)
|
2018-02-07 |
2019-08-15 |
Insmed Incorporated |
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides
|
|
HUE070049T2
(hu)
|
2018-03-01 |
2025-05-28 |
Astrazeneca Ab |
(2S)-{(1S)-1-ciano-2-[4-(3-metil-2-oxo-2,3-dihidro-1,3-benzoxazol-5-il)fenil]etil} -1,4-oxazepán-2-karboxamidot tartalmazó gyógyászati készítmények
|
|
US20210252015A1
(en)
|
2018-07-17 |
2021-08-19 |
Insmed Incorporated |
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease
|
|
WO2020018547A1
(en)
|
2018-07-17 |
2020-01-23 |
Insmed Incorporated |
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
|
|
MX2021012548A
(es)
|
2019-04-17 |
2023-01-05 |
Azora Therapeutics Inc |
Composiciones topicas y metodos para el tratamiento de enfermedades inflamatorias de la piel.
|
|
BR112021024310A2
(pt)
|
2019-06-05 |
2022-02-15 |
Univ Emory |
Peptidomiméticos para o tratamento de infecções por coronavírus e picornavírus
|
|
WO2022140516A1
(en)
|
2020-12-22 |
2022-06-30 |
Insmed Incorporated |
Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
|
|
CN112920124B
(zh)
|
2021-01-29 |
2024-03-01 |
安徽医科大学 |
一种嘧啶-2,4-二胺类化合物及其制备方法与应用
|
|
US20240226112A1
(en)
|
2021-04-29 |
2024-07-11 |
Insmed Incorporated |
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
|
|
WO2022232420A1
(en)
|
2021-04-29 |
2022-11-03 |
Insmed Incorporated |
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
|
|
CA3236069A1
(en)
|
2021-10-29 |
2023-05-04 |
Ariel Teper |
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating chronic rhinosinusitis
|
|
EP4479059A4
(en)
|
2022-02-16 |
2026-01-28 |
Insmed Inc |
CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE
|